NFATC2 and synucleinopathy: To address this hypothesis, we used a synucleinopathy mouse model, which overexpresses human wild-type α-syn under the murine Thy1 promotor, and administrated 11R-VIVIT, a selective cell-permeable NFAT1 inhibitor.